Danaher Corp stock falls amid portfolio adjustments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2025
0mins
Should l Buy DHR?
Source: MarketWatch
Danaher Corp's stock has dropped 3.02% and hit a 20-day low amid a broader market decline, with the Nasdaq-100 down 1.18% and the S&P 500 down 0.99%.
The decline in Danaher’s stock is attributed to a strategic portfolio adjustment by investors, who have increased their stake in Cardinal Health while reducing their holdings in Danaher. This shift reflects a response to market conditions rather than any specific negative news about Danaher itself.
This movement indicates a potential reallocation of investments within the healthcare sector, as investors seek to capitalize on perceived opportunities in other companies while Danaher faces pressure from broader market trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 189.600
Low
240.00
Averages
266.18
High
310.00
Current: 189.600
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
See More
Stock Performance Comparison: DHR vs. PODD
- Stock Performance Comparison: DHR is currently trading up approximately 0.4%, while PODD is up about 1.6%, indicating differing market performances that could influence investor choices and market confidence.
- Market Dynamics Analysis: The midday trading on Thursday shows contrasting price movements for DHR and PODD, which may reflect varying investor perceptions tied to each company's business performance and market expectations.
- Investor Focus: The price changes of DHR and PODD could significantly impact investor decisions, especially in the context of increasing competition within the medical device sector, prompting investors to closely monitor upcoming financial reports and market trends.
- Industry Trend Impact: As the medical device industry continues to evolve, the stock fluctuations of DHR and PODD may be influenced by industry trends and technological innovations, necessitating that investors consider these factors for informed investment decisions.
See More
Danaher Corporation Schedules Q1 2026 Earnings Call
- Earnings Call Scheduled: Danaher Corporation will hold its Q1 2026 earnings conference call on April 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which financial performance and future expectations will be discussed.
- Webcast Details: The call will be webcast on Danaher's website under the 'Investors' section, with accompanying slides available, ensuring real-time information access for investors.
- Replay Availability: A replay of the conference call will be available until May 5, 2026, allowing investors to access the information by dialing the specified numbers, enhancing information accessibility.
- Company Overview: Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology, with approximately 60,000 associates focused on scientific excellence and innovation.
See More
Danaher Corporation Schedules Q1 2026 Earnings Call
- Earnings Call Scheduled: Danaher Corporation will hold its Q1 2026 earnings conference call on April 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Details: The call and accompanying slide presentation will be webcast on the 'Investors' section of Danaher's website, ensuring that investors can access key information in real-time.
- Replay Availability: A replay of the conference call will be available until May 5, 2026, allowing investors who cannot attend live to review the discussion.
- Financial Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, ensuring investors have access to the latest financial data and analysis before the meeting.
See More
Halper Sadeh LLC Investigates Danaher Corporation Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers of Danaher Corporation breached their fiduciary duties, potentially leading to financial losses for shareholders and impacting corporate governance.
- Legal Fee Arrangement: The firm offers legal services on a contingent fee basis, ensuring shareholders do not incur upfront costs while pursuing their rights, thereby encouraging broader participation.
- Importance of Shareholder Involvement: Active shareholder participation can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, showcasing their expertise in protecting investor rights.
See More
Analysis of Increased Stake in Cardinal Health
- Increased Stake: We purchased 90 shares of Cardinal Health at approximately $217, raising our total holdings to 350 shares and increasing its weight from 1.46% to about 2%, demonstrating confidence in the company's future growth potential.
- Market Performance Analysis: Despite the healthcare sector's poor performance this week, Cardinal Health's stock drop is not tied to fundamentals, providing more upside to our $260 price target, reflecting a misunderstanding of the stock by the market.
- Industry Dynamics: The drug distribution sector is under pressure, particularly McKesson, which saw a 5% drop in shares following the announcement of its longtime CFO's retirement, indicating market sensitivity to leadership changes, even though this transition was planned.
- Investment Strategy: We are leveraging our ample cash position to increase our stake in Cardinal Health, replacing our exit from Danaher, which has fallen about 3% since last week, showcasing our ability to flexibly adjust our portfolio amid market fluctuations.
See More
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
See More
Stock Performance Comparison: DHR vs. PODD
- Stock Performance Comparison: DHR is currently trading up approximately 0.4%, while PODD is up about 1.6%, indicating differing market performances that could influence investor choices and market confidence.
- Market Dynamics Analysis: The midday trading on Thursday shows contrasting price movements for DHR and PODD, which may reflect varying investor perceptions tied to each company's business performance and market expectations.
- Investor Focus: The price changes of DHR and PODD could significantly impact investor decisions, especially in the context of increasing competition within the medical device sector, prompting investors to closely monitor upcoming financial reports and market trends.
- Industry Trend Impact: As the medical device industry continues to evolve, the stock fluctuations of DHR and PODD may be influenced by industry trends and technological innovations, necessitating that investors consider these factors for informed investment decisions.
See More
Danaher Corporation Schedules Q1 2026 Earnings Call
- Earnings Call Scheduled: Danaher Corporation will hold its Q1 2026 earnings conference call on April 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which financial performance and future expectations will be discussed.
- Webcast Details: The call will be webcast on Danaher's website under the 'Investors' section, with accompanying slides available, ensuring real-time information access for investors.
- Replay Availability: A replay of the conference call will be available until May 5, 2026, allowing investors to access the information by dialing the specified numbers, enhancing information accessibility.
- Company Overview: Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology, with approximately 60,000 associates focused on scientific excellence and innovation.
See More
Danaher Corporation Schedules Q1 2026 Earnings Call
- Earnings Call Scheduled: Danaher Corporation will hold its Q1 2026 earnings conference call on April 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Details: The call and accompanying slide presentation will be webcast on the 'Investors' section of Danaher's website, ensuring that investors can access key information in real-time.
- Replay Availability: A replay of the conference call will be available until May 5, 2026, allowing investors who cannot attend live to review the discussion.
- Financial Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, ensuring investors have access to the latest financial data and analysis before the meeting.
See More
Halper Sadeh LLC Investigates Danaher Corporation Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers of Danaher Corporation breached their fiduciary duties, potentially leading to financial losses for shareholders and impacting corporate governance.
- Legal Fee Arrangement: The firm offers legal services on a contingent fee basis, ensuring shareholders do not incur upfront costs while pursuing their rights, thereby encouraging broader participation.
- Importance of Shareholder Involvement: Active shareholder participation can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, showcasing their expertise in protecting investor rights.
See More
Analysis of Increased Stake in Cardinal Health
- Increased Stake: We purchased 90 shares of Cardinal Health at approximately $217, raising our total holdings to 350 shares and increasing its weight from 1.46% to about 2%, demonstrating confidence in the company's future growth potential.
- Market Performance Analysis: Despite the healthcare sector's poor performance this week, Cardinal Health's stock drop is not tied to fundamentals, providing more upside to our $260 price target, reflecting a misunderstanding of the stock by the market.
- Industry Dynamics: The drug distribution sector is under pressure, particularly McKesson, which saw a 5% drop in shares following the announcement of its longtime CFO's retirement, indicating market sensitivity to leadership changes, even though this transition was planned.
- Investment Strategy: We are leveraging our ample cash position to increase our stake in Cardinal Health, replacing our exit from Danaher, which has fallen about 3% since last week, showcasing our ability to flexibly adjust our portfolio amid market fluctuations.
See More
